Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event

Rhea-AI Summary

On December 29, 2021, Selecta Biosciences, Inc. (NASDAQ: SELB) announced its participation in the LifeSci Partners 11th Annual Corporate Access Event, scheduled for January 5-7, 2022. The company will take part in a panel discussion titled “Gene Therapy: Reaching its Full Potential” on January 6, 2022, at 11:00 AM ET. Investors can access the live webcast via the provided link. Selecta is known for its ImmTOR™ platform, which develops therapies aimed at mitigating immune responses and enhancing therapies for autoimmune diseases and gene therapy redosing.

WATERTOWN, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will participate in a panel and one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.

Details on the panel can be found below.

LifeSci Partners 11th Annual Corporate Access Event
Panel Topic: “Gene Therapy: Reaching its Full Potential”
Date: Thursday, January 6, 2022
Time: 11:00 AM ET
Webcast link: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

FAQ

When will Selecta Biosciences participate in the LifeSci Partners Corporate Access Event?

Selecta Biosciences will participate in the event from January 5-7, 2022.

What is the topic of Selecta Biosciences' panel at the event?

The panel topic is 'Gene Therapy: Reaching its Full Potential'.

What date and time is Selecta's panel scheduled?

Selecta's panel is scheduled for January 6, 2022, at 11:00 AM ET.

Where can I find the webcast for Selecta's panel discussion?

The webcast can be accessed through the link provided in the press release.

What is the main focus of Selecta Biosciences' ImmTOR™ platform?

The ImmTOR™ platform focuses on developing therapies that mitigate unwanted immune responses.